Aptose Biosciences, Inc. Employee Directory
Biotechnology ResearchCalifornia, United States11-50 Employees
Aptose Biosciences is a science-driven, clinical-stage biotechnology company focused on developing targeted therapies for hematologic cancers with unmet clinical needs. Its CG-806 program centers on an oral, mutation-agnostic inhibitor of FLT3 and BTK that is being developed for certain B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and select non-Hodgkin's lymphomas in patients who are resistant or intolerant to conventional treatments, as well as for relapsed or refractory acute myeloid leukemia, including populations resistant to approved targeted therapies. APTO-253, the company's first-in-class MYC inhibitor, is being developed for relapsed or refractory AML or myelodysplastic syndrome.